Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1675
Peer-review started: January 18, 2022
First decision: March 8, 2022
Revised: March 23, 2022
Accepted: August 6, 2022
Article in press: August 6, 2022
Published online: September 15, 2022
Six-transmembrane epithelial antigen of the prostate 4 (STEAP4) is an attractive biomarker for the immunotherapy of prostate and breast cancers. However, the immunotherapeutic role of STEAP4 for colorectal carcinomas has not been demonstrated.
Immunotherapy emerges with predicting outcomes and therapeutic efficacy in colorectal cancers (CRC).
To explore the expression pattern of STEAPs in CRCs and their relationship with immune infiltration, and investigate the potential utilization of STEAPs as novel prognostic indicators in colorectal carcinomas.
CRC patients’ tissues and online datasets were used to analyze the expression level of STEAP4 in different types of CRC and their relationship with immune characteristics.
The expression of STEAP4 was significantly decreased in CRC tissues compared with adjacent normal ones, and was related to immune-related biomarkers. Low STEAP4 level predicted a poor overall survival of CRC patients.
STEAP4 was found to be a protective factor in the intestinal tract and could be used as a prognostic indicator for patients with CRC.
STEAP4 may be a potential biomarker for predicting CRC immune infiltration status.